Effects of synthetic peptides on the inflammatory response and their therapeutic potential

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 553-564

  Rita, Selvatici ^a   Anna, Siniscalchi ^b   Susanna, Spisani ^c  

^a Sezione di Genetica Medica   (Italy)

^b Dipartimento di Medicina Clinica e Sperimentale   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Chemotaxis; Formylpeptide receptor; Inflammation; Lysozyme release; Neuroprotection; Protein kinase C inhibition; Superoxide anion; Synthetic peptides

Indexed keywords

ACETYLCHOLINE; AMINO TERMINAL PEPTIDE 5; AMINO TERMINAL PEPTIDE 8; AMINO TERMINAL PEPTIDE 9; DEXAMETHASONE; FORMYLPEPTIDE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GF109203X; GLUTAMIC ACID; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; PROTEIN KINASE INHIBITOR 55; SB20358; STRESS ACTIVATED PROTEIN KINASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AGONIST; AMINO ACID SEQUENCE; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BRAIN ISCHEMIA; ENZYME ACTIVITY; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PEPTIDE SYNTHESIS; REVIEW;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMOTAXIS; HUMANS; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PEPTIDES; PROTEIN BINDING; PROTEIN KINASE C; PROTEINS; RECEPTORS, FORMYL PEPTIDE; SUPEROXIDES;

EID: 84875301944     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313040008     Document Type: Review

References (75)

1. Kennedy, A.D.; De Leo, F.R. Neutrophil apoptosis and the resolution of infection. Immunol. Res., 2009, 43, 25-61.
2. Karlsson, J.; Bylund, J.; Movitz, C.; Björkman, L.; Forsman, H.; Dahlgren, C.A. Methodological approach to studies of desensitization of the formyl peptide receptor: Role of the read out system, reactive oxygen species and the specific agonist used to trigger neutrophils. J. Immunol. Methods, 2010, 352, 45-53.
3. Bagorda, A.; Mihaylov, V.A.; Parent, C.A. Chemotaxis: moving forward and holding on to the past. Thromb. Haemost., 2006, 95, 12-21.
4. Viola, A.; Luster, A.D. Chemokines and their Receptors: Drug Targets in Immunity and Inflammation. Annu. Rev. Pharmacol. Toxicol., 2008. 48, 171-97.
5. Andersson, T.; Dahlgren, C.; Pozzan, T.; Stendahl, O.; Lew, P.D. Characterization of fMet-Leu-Phe receptor mediated Ca2+ influx across the plasma membrane of human neutrophils. Mol. Pharmacol., 1986, 30, 437-43.
6. Berg, M.; James, S.P. Human neutrophils release the Leu-8 lymph node homing receptor during cell activation. Blood, 1990, 76, 2381-8.
7. Huber, A.R.; Kunkel, S.L.; Todd III, R. F.; Weiss, S.J. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science, 1991, 254, 99-102.
8. Fu, H.; Bylund, J.; Karlsson, A.; Pellme, S.; Dahlgren, C. The mechanism for activation of the neutrophil NADPH oxidase by the peptides formyl-Met-Leu-Phe and Trp-Lys-Tyr-Met-Val-Met differs from that for interleukin-8. Immunology, 2004, 112, 201-10.
9. Quinn, M.T.; Ammon, M.C.; DeLeo, F.R. The expanding role of NADPH oxidases in health and disease: no longer just agents of death and destruction. Clin Sci. (Lond), 2006, 111, 1-20.
10. Servant, G.; Weiner, O.D.; Herzmark, P.; Balla, T.; Sedat, J.W.; Bourne, H.R. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science, 2000, 287, 1037-40.
11. Jin, T.; Xu, X.; Fang, J.; Isik, N.; Yan, J.; Brzostowski, J.A.; Hereld, D. How human leukocytes track down and destroy pathogens: lessons learned from the model organism Dictyostelium discoideum. Immunol. Res., 2009, 43, 118-27.
12. Le, Y.Y.; Murphy, M.; Wang, J.M. Formyl-peptide receptors revisited. Trends Immunol., 2002, 23, 541-8.
13. Ye, R. D,; Boulay, F.; Wang, J. I. M,; Dahlgren, C.; Gerard, C.; Parmentier, M.; Serhan C. N.; Murphy P. M. Nomenclature for the Formyl Peptide Receptor (FPR) Family. Pharmacol Rev., 2009, 61, 119-61.
14. Boulay, F.M.; Brouchon, T.L.; Vignais, P. The human Nformylpeptide receptor: characterization of two cDNAisolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry, 1990, 29, 11123-33.
15. Cockcroft, S. G-protein-regulated phospholipases C, D and A2-mediated signalling in neutrophils. Biochim. Biophys. Acta, 1992, 1113, 135-60.
16. Seifert, R., Wenzel-Seifert, K. The human formyl peptide receptor as model system for constitutively active G protein-coupled receptors. Life Sci., 2003, 73, 2263-80.
17. Murphy, P.M.; Ozcelik, T.; Kenney, R.T.; Tiffany, H.L.; McDermott, D.; Francke, U.A. Structural homologue of the Nformyl peptide receptor: characterization and chromosome mapping of a peptide chemoattractant receptor family. J. Biol. Chem., 1992, 267, 7637-43.
18. Young, S. M,; Bologa, C. M,; Dan Fara, B.; Bryant, B.K.; Strouse, J.J.; Arterburn, J.B.; Duplex High Throughput Flow Cytometry Screen Identifies Two Novel Formylpeptide Receptor Family Probes. Cytometry A., 2009, 75, 253-63.
19. VanCompernolle, S.E.; Clark, K.L.; Rummel, K.A.; Todd, S.C. Expression and function of formyl peptide receptors on human fibroblast cells. J. Immunol., 2003, 171, 2050-6.
20. Bae, Y.S.; Lee, H.Y.; Jo, E.J.; Kim, J.I.; Kang, H.K.; Ye, R.D.; Kwak, J.Y.; Ryu, S.H. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J. Immunol., 2004, 173, 607-14.
21. Fu, H.; Karlsson, J.; Bylund, J.M.; Movitz, C.; Karlsson, A.; Dahlgren, C. Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leuk. Biol., 2006, 80, 247-56.
22. Migeotte, I.; Communi, D.; Parmentier, M. Formyl peptide receptors: a promiscuous subfamily of G protein coupled receptors controlling immune responses, Cytokine Growth Factor Rev., 2006, 17, 501-19.
23. Waters, C.; Pyne, S.; Pyne. N.J. The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Seminars Cell. Devel. Biol., 2004, 15, 309-23.
24. Lehman, J.A.; Gomez-Cambronero, J. Molecular crosstalk between p70S6k and MAPK cell signaling pathways. Biochem. Biophys. Res. Commun., 2002, 293, 463-9.
25. Forrest, A. R; Ravasi, T.; Taylor, D.; Huber, T.; Hume, D.A.; Grimmond, S. Phosphoregulators: protein kinases and protein phosphatases of mouse. Genome Res., 2003,13, 1443-54.
26. Cowan, K.J.; Storey, K.B. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J. Exp. Biol., 2003, 206, 1107-15.
27. Kyriakis, J.M.; Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev., 2001, 8, 807-69.
28. Zhang, J.; Shen, B.; Lin, A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci., 2007, 28, 286-95.
29. Kaminska, B.; Gozdz, A.; Zawadzka, M.; Ellert-Miklaszewska, A.; Lipko, M. MAPK signal transduction underlying brain inflammation and gliosis as therapeutic target. Anat. Rec. (Hoboken), 2009, 292, 1902-13.
30. Miloso, M.; Scuteri, A.; Foudah, D.; Tredici, G. MAPKs as mediators of cell fate determination: an approach to neurodegenerative diseases. Curr. Med. Chem., 2008, 15, 538-48.
31. Bertram, A.; Ley, K. Protein kinase C isoforms in neutrophil adhesion and activation. Review. Arch. Immunol. Therap. Exp., 2011, 59, 79-87.
32. Corbalán-García, S.; Gómez-Fernández, J.C. Protein kinase C regulatory domains: the art of decoding many different signals in membranes. Review. Biochim Biophys Acta, 2006, 1761, 633-54.
33. Spisani, S.; Pareschi, M.C.; Buzzi, M.; Colamussi, M.L.; Biondi, C.; Traniello, S.; Pagani Zecchini, G.; Paglialunga Paradisi, M.; Torrini, I.; Ferretti, M.E. Effect of cyclic AMP level reduction on human neutrophil responses to formylated peptides. Cell Signal., 1996, 8, 269-77.
34. Ferretti, M.E., Spisani, S.; Pareschi, M.C.; Buzzi, M.; Cavallaro, R.; Traniello, S.; Reali, E.; Torrini, I.; Paglialunga Paradisi, M.; Pagani Zecchini, G.; Biondi, C. Two new formylated peptides able to selectively activate chemotaxis and respiratory burst as tools for studying human neutrophil response. Cell. Signal., 1994, 6, 91-101.
35. Torrini, I.; Pagani Zecchini, G.; Paglialunga Paradisi, M.; Lucente, G.; Gavuzzo, E.; Mazza, F.; Pochetti, G.; Spisani, S.; Giuliani, A.L. Synthesis and properties of chemotactic peptide analogs. II. HCOMet-Leu-Phe-OMe analogs containing cyclic alpha, alphadisubstituted amino acids as Met and Phe mimicking residues. Int. J. Pept. Protein Res., 1991, 38, 495-04.
36. Pagani Zecchini, G.; Paglialunga Paradisi, M.; Torrini, I.; Lucente, G.; Gavuzzo, E.; Mazza, F.; Pochetti, G.; Paci, M.; Sette, M.; Di Nola, A.; Veglia, G.; Traniello, S.; Spisani, S. Synthesis, conformation and activity of For-Met-zLeu-Phe-OMe, an active analog of chemotactic N-formyltripeptides. Biopolymers, 1993, 33, 437-51.
37. Fabbri, E.; Spisani, S.; Barbin, L.; Biondi, C.; Buzzi, M.; Traniello, S.; Pagani Zecchini, G.; Ferretti, M.E. Studies on fMLP-receptor interaction and signal transduction pathway by means of fMLPOMe selective analogues. Cell. Signal., 2000, 12, 391-8.
38. Fabbri, E.; Spisani, S.; Biondi, C.; Barbin, L., Colamussi, M.L.; Cariani, A.; Traniello, S.; Torrini, I.; Ferretti, M.E. Two for-Met-Leu-Phe-OMe analogues trigger selective neutrophil responses: A differential effect on cytosolic free Ca2+. Biochim. Biophys. Acta, 1997, 1359, 233-40.
39. Ferretti, M.E.; Spisani, S.; Pareschi, M.C.; Buzzi, M.; Cavallaro, R.; Traniello, S.; Reali, E.; Torrini, I.; Paglialunga Paradisi, M.; Pagani Zecchini, G.; Biondi, C. Two new formylated peptides able to selectively activate chemotaxis and respiratory burst as tools for studying human neutrophil response. Cell. Signal., 1994, 6, 91-101.
40. Ferretti, M.E.; Nalli, M.; Biondi, C.; Colamussi, L.; Pavan, B.; Traniello, S.; Spisani, S. Modulation of neutrophil phospholipase C activity and cyclic AMP levels by fMLP-OMe analogues. Cell Signal., 2001, 13, 233-40.
41. Spisani, S., Falzarano, S.; Traniello, S.; Nalli, M.; Selvatici, R. A 'pure' chemoattractant formylpeptide analogue triggers a specific signalling pathway in human neutrophil chemotaxis. FEBS J., 2005, 272, 883-91.
42. Selvatici, R.; Falzarano, S.; Traniello, S.; Pagani Zecchini, G.; Spisani, S. Formylpeptides trigger selective molecular pathways that are required in the physiological functions of human neutrophils. Cell Signal., 2003, 15, 377-83.
43. Aswanikumar, S.; Corcoran, B.A.; Schiffman, E. Peptides with agonist and antagonist chemotactic activity. In: Peptides, Goodman, M.; Meinhofer, J. Eds; Wiley, New York 1977; pp. 141-45.
44. Dalpiaz, A.; Ferretti, M.E.; Pecoraro, R.; Fabbri, E.; Traniello, S.; Scatturin, A.; Spisani, S. Phe-D-Leu-Phe-D-Leu-Phe derivatives as formylpeptide receptor antagonists in human neutrophils: cellular and conformational aspects. Biochim. Biophys. Acta, 1999, 1432, 27-39.
45. Edwards, B.S.; Bologa, C.; Young, S.M.; Balakin, K.V.; Prossnitz, E.R.; Savchuck, N.P.; Sklar, L.A.; Oprea, T.I. Integration of virtual screening with high throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol. Pharmacol. 2005, 68, 1301-10.
46. Dalpiaz, A.; Ferretti, M.E.; Vertuani, G.; Traniello, S.; Scatturin, A.; Spisani, S. C-and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor. Eur. J. Pharmacol., 2002, 436, 187-96.
47. Dalpiaz, A.; Spisani, S.; Biondi, C.; Fabbri, E.; Nalli, M.; Ferretti, M.E. Studies on human neutrophil biological functions by means of formyl-peptide receptor agonists and antagonists. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2003, 3, 33-42.
48. Selvatici, R.; Melloni, E.; Ferrati, M.; Piubello, C.; Marincola, F.C.; Gandini, E. Adaptative value of a PKC-PKI55 feedback loop of inhibition that prevents the kinase's deregulation. J. Mol. Evol., 2003, 57, 131-9.
49. Buchner, K. The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus. J. Cancer. Res. Clin. Oncol., 2000, 126, 1-11.
50. Selvatici, R.; Falzarano, S.; Franceschetti, L.; Spisani, S.; Siniscalchi, A. Effects of PKI55 protein, an endogenous protein kinase C modulator, on specific PKC isoforms activity and on human T cells proliferation. Arch. Biochem. Biophys., 2007, 462, 74-82.
51. Borgatti, M.; Finotti, A.; Falzarano, S.; Selvatici R. Structural characterization of promoter sequences of the gene coding human PKI55 protein, a protein kinase C inhibitor. Biochimie, 2009, 91, 466-74.
52. Selvatici, R.; Falzarano, S.; Franceschetti, L.; Mollica, A.; Guerrini, R.; Siniscalchi, A.; Spisani, S. Study of synthetic peptides derived from the PKI55 protein, a protein kinase C modulator, in human neutrophils stimulated by the methyl ester derivative of the hydrophobic N-formyl tripeptide for-Met-Leu-Phe-OH. FEBS J., 2008, 275, 449-57.
53. Selvatici, R.; Congestrì, F.; Marzola, G.; Guerrini, R.; Siniscalchi, A.; Spisani, S. Anti-inflammatory and analgesic effects displayed by peptides derived from PKI55 protein, an endogenous protein kinase C inhibitor. Naunyn Schmiedebergs Arch. Pharmacol., 2010, 382, 193-9.
54. Pascale, A.; Amadio, M.; Govoni, S.; Battaini, F. The aging brain, a key target for the future: the protein kinase C involvement. Pharmacol. Res., 2007, 55, 560-9.
55. Selvatici. R.; Marino, S.; Piubello, C.; Rodi, D.; Beani, L.; Gandini, E.; Siniscalchi, A. Protein kinase C activity, translocation, and selective isoform subcellular redistribution in the rat cerebral cortex after in vitro ischemia. J. Neurosci. Res., 2003, 71, 64-71.
56. Lau, A.; Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch., 2010, 460, 525-42.
57. Wang, Y.; Qin, Z.H. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis, 2010, 15, 1382-402.
58. Badini, I.; Beani, L.; Bianchi, C.; Marzola, G.; Siniscalchi, A. Postischemic recovery of acetylcholine release in vitro: influence of different excitatory amino acid receptor subtype antagonists. Neurochem. Int., 1997, 31, 817-24.
59. Wang, J.; Bright, R.; Mochly-Rosen, D.; Giffard, R.G. Cellspecific role for epsilon-and betaI-protein kinase C isozymes in protecting cortical neurons and astrocytes from ischemia-like injury. Neuropharmacology, 2004, 47, 136-45.
60. Bright, R.; Mochly-Rosen, D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke, 2005, 36, 2781-90.
61. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today, 2010, 15, 40-56.
62. Grainger, D. J.; Reckless, J. Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo. Biochem. Pharmacol., 2003, 65, 1027-34.
63. Mackay, H. J; Twelves, C.J. Targeting the protein kinase C family: are we there yet? Natl. Rev. Cancer, 2007, 7, 554-62.
64. Churchill, E.; Budas, G.; Vallentin, A.; Koyanagi, T.; Mochly-Rosen, D. PKC Isozymes in chronic cardiac disease: possible therapeutic targets? Annu. Rev. Pharmacol. Toxicol., 2008, 48, 569-99.
65. Dempsey, E.C.; Cool, C.D.; Littler, C.M. Lung disease and PKCs. Pharmacol. Res., 2007, 55, 545-59.
66. Aksoy, E.; Goldman, M.; Willems, F. Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int. J. Biochem. Cell. Biol., 2004, 36, 183-88.
67. Das Evcimen, N.; King, G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res., 2007, 55, 498-510.
68. Zarate, C.A.; Manji, H.K. Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder. CNS Drugs, 2009, 23, 569-82.
69. de Barry, J.; Liégeois, C.M.; Janoshazi, A. Protein kinase C as a peripheral biomarker for Alzheimer's disease. Exp. Gerontol., 2010, 45, 64-69.
70. Mukohara, T.; Nagai, S.; Koshiji, M.; Yoshizawa, K.; Minami, H. Phase I dose escalation and pharmacokinetic study of oral enzastaurin (LY317615) in advanced solid tumors. Cancer Sci., 2010, 101, 2193-99.
71. Mehta, N.N.; Sheetz, M.; Price, K.; Comiskey, L.; Amrutia, S.; Iqbal, N.; Mohler, E.R.; Reilly, M.P. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. Cardiovasc Drugs Ther., 2009, 23, 17-24.
72. Yildiz, A.; Guleryuz, S.; Ankerst, D.P.; Ongür, D.; Renshaw, P.F. Protein kinase C inhibition in the treatment of mania: a doubleblind, placebo-controlled trial of tamoxifen. Arch. Gen. Psychiatry, 2008, 65, 255-63.
73. Kuchera, S.; Barth, H.; Jacobson, P.; Metz, A.; Schaechtele, C.; Schrier, D. Anti-inflammatory properties of the protein kinase C inhibitor, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-1Hpyrrole-2,5-dione monohydrochloride (GF109203X) in the PMAmouse ear edema model. Agents Actions, 1993, 39 Spec No., C169-73.
74. Merritt, J.E.; Sullivan, J.A.; Tse, J.; Wilkinson, S.; Nixon, J.S. Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction. Cell. Signal., 1997, 9, 53-7.
75. Shin, O.S.; Behera, A.K.; Bronson, R.T.; Hu, L.T. Role of novel protein kinase C isoforms in Lyme arthritis. Cell. Microbiol., 2007, 9, 1987-96.